Chinese guidelines related to novel coronavirus pneumonia.
Identifieur interne : 000907 ( Main/Corpus ); précédent : 000906; suivant : 000908Chinese guidelines related to novel coronavirus pneumonia.
Auteurs : Tingting Qiu ; Shuyao Liang ; Monique Dabbous ; Yitong Wang ; Ru Han ; Mondher ToumiSource :
- Journal of market access & health policy [ 2001-6689 ] ; 2020.
Abstract
Background and Objective: China has managed to control the coronavirus disease (COVID-19) with confinement measurements and treatment strategies, while other countries are struggling to contain the spread. This study discusses the guidelines related to COVID-19 in China in order to provide important references for other countries in the fight against COVID-19. Methods: Chinese guidelines relevant to COVID-19 were systematically searched via the China National Knowledge Infrastructure database, YiMaiTong database, and World Health Organization (WHO) COVID-19 database on March 20th, 2020. Guideline information was extracted, including date of publication, source, objectives and the target population. Guidelines specific to the pharmacological treatment of COVID-19 were further investigated to identify the types of antivirus drugs recommended and to report on how treatment recommendations for COVID-19 have evolved overtime. Results: A total of 100 guidelines were identified, of which 74 were national guidelines and 26 were regional guidelines. The scope of included guidelines consisted of: the diagnosis and treatment of COVID-19, the management of hospital departments and specific diseases during the outbreak of COVID-19. Fifty-one of the included guidelines targeted overall COVID-19 patients, while the remaining guidelines concentrated on special patient populations (i.e. geriatric population, pediatric population, and pregnant population) or patients with coexisting diseases. Fifteen guidelines focused on the pharmacological treatments for all COVID-19 patients. Interferon, Lopinavir/Ritonavir, Ribavirin, Chloroquine, and Umifenovir represented the most recommended antivirus drugs. Among them, 7 Chinese guidelines have recommended Chloroquine Phosphate or Hydroxychloroquine for the treatment of COVID-19. Conclusions: China has generated a plethora of guidelines covering almost all aspects of COVID-19. Chloroquine, as one widely affordable treatment, was recommended by Chinese national guidelines and provincial guidelines. Considering the continuous debates around Chloroquine, confirmatory studies with robust methodology are awaited to address the unanswered questions on its potential benefits and risks on COVID-19.
DOI: 10.1080/20016689.2020.1818446
PubMed: 33133431
PubMed Central: PMC7580738
Links to Exploration step
pubmed:33133431Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chinese guidelines related to novel coronavirus pneumonia.</title><author><name sortKey="Qiu, Tingting" sort="Qiu, Tingting" uniqKey="Qiu T" first="Tingting" last="Qiu">Tingting Qiu</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Liang, Shuyao" sort="Liang, Shuyao" uniqKey="Liang S" first="Shuyao" last="Liang">Shuyao Liang</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dabbous, Monique" sort="Dabbous, Monique" uniqKey="Dabbous M" first="Monique" last="Dabbous">Monique Dabbous</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Yitong" sort="Wang, Yitong" uniqKey="Wang Y" first="Yitong" last="Wang">Yitong Wang</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Han, Ru" sort="Han, Ru" uniqKey="Han R" first="Ru" last="Han">Ru Han</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Toumi, Mondher" sort="Toumi, Mondher" uniqKey="Toumi M" first="Mondher" last="Toumi">Mondher Toumi</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33133431</idno><idno type="pmid">33133431</idno><idno type="doi">10.1080/20016689.2020.1818446</idno><idno type="pmc">PMC7580738</idno><idno type="wicri:Area/Main/Corpus">000907</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000907</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Chinese guidelines related to novel coronavirus pneumonia.</title><author><name sortKey="Qiu, Tingting" sort="Qiu, Tingting" uniqKey="Qiu T" first="Tingting" last="Qiu">Tingting Qiu</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Liang, Shuyao" sort="Liang, Shuyao" uniqKey="Liang S" first="Shuyao" last="Liang">Shuyao Liang</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Dabbous, Monique" sort="Dabbous, Monique" uniqKey="Dabbous M" first="Monique" last="Dabbous">Monique Dabbous</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Yitong" sort="Wang, Yitong" uniqKey="Wang Y" first="Yitong" last="Wang">Yitong Wang</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Han, Ru" sort="Han, Ru" uniqKey="Han R" first="Ru" last="Han">Ru Han</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author><author><name sortKey="Toumi, Mondher" sort="Toumi, Mondher" uniqKey="Toumi M" first="Mondher" last="Toumi">Mondher Toumi</name><affiliation><nlm:affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of market access & health policy</title><idno type="ISSN">2001-6689</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Background and Objective:</b> China has managed to control the coronavirus disease (COVID-19) with confinement measurements and treatment strategies, while other countries are struggling to contain the spread. This study discusses the guidelines related to COVID-19 in China in order to provide important references for other countries in the fight against COVID-19. <b>Methods:</b> Chinese guidelines relevant to COVID-19 were systematically searched via the China National Knowledge Infrastructure database, YiMaiTong database, and World Health Organization (WHO) COVID-19 database on March 20<sup>th</sup>, 2020. Guideline information was extracted, including date of publication, source, objectives and the target population. Guidelines specific to the pharmacological treatment of COVID-19 were further investigated to identify the types of antivirus drugs recommended and to report on how treatment recommendations for COVID-19 have evolved overtime. <b>Results:</b> A total of 100 guidelines were identified, of which 74 were national guidelines and 26 were regional guidelines. The scope of included guidelines consisted of: the diagnosis and treatment of COVID-19, the management of hospital departments and specific diseases during the outbreak of COVID-19. Fifty-one of the included guidelines targeted overall COVID-19 patients, while the remaining guidelines concentrated on special patient populations (i.e. geriatric population, pediatric population, and pregnant population) or patients with coexisting diseases. Fifteen guidelines focused on the pharmacological treatments for all COVID-19 patients. Interferon, Lopinavir/Ritonavir, Ribavirin, Chloroquine, and Umifenovir represented the most recommended antivirus drugs. Among them, 7 Chinese guidelines have recommended Chloroquine Phosphate or Hydroxychloroquine for the treatment of COVID-19. <b>Conclusions</b>: China has generated a plethora of guidelines covering almost all aspects of COVID-19. Chloroquine, as one widely affordable treatment, was recommended by Chinese national guidelines and provincial guidelines. Considering the continuous debates around Chloroquine, confirmatory studies with robust methodology are awaited to address the unanswered questions on its potential benefits and risks on COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33133431</PMID><DateRevised><Year>2021</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2001-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Journal of market access & health policy</Title><ISOAbbreviation>J Mark Access Health Policy</ISOAbbreviation></Journal><ArticleTitle>Chinese guidelines related to novel coronavirus pneumonia.</ArticleTitle><Pagination><MedlinePgn>1818446</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/20016689.2020.1818446</ELocationID><Abstract><AbstractText><b>Background and Objective:</b> China has managed to control the coronavirus disease (COVID-19) with confinement measurements and treatment strategies, while other countries are struggling to contain the spread. This study discusses the guidelines related to COVID-19 in China in order to provide important references for other countries in the fight against COVID-19. <b>Methods:</b> Chinese guidelines relevant to COVID-19 were systematically searched via the China National Knowledge Infrastructure database, YiMaiTong database, and World Health Organization (WHO) COVID-19 database on March 20<sup>th</sup>, 2020. Guideline information was extracted, including date of publication, source, objectives and the target population. Guidelines specific to the pharmacological treatment of COVID-19 were further investigated to identify the types of antivirus drugs recommended and to report on how treatment recommendations for COVID-19 have evolved overtime. <b>Results:</b> A total of 100 guidelines were identified, of which 74 were national guidelines and 26 were regional guidelines. The scope of included guidelines consisted of: the diagnosis and treatment of COVID-19, the management of hospital departments and specific diseases during the outbreak of COVID-19. Fifty-one of the included guidelines targeted overall COVID-19 patients, while the remaining guidelines concentrated on special patient populations (i.e. geriatric population, pediatric population, and pregnant population) or patients with coexisting diseases. Fifteen guidelines focused on the pharmacological treatments for all COVID-19 patients. Interferon, Lopinavir/Ritonavir, Ribavirin, Chloroquine, and Umifenovir represented the most recommended antivirus drugs. Among them, 7 Chinese guidelines have recommended Chloroquine Phosphate or Hydroxychloroquine for the treatment of COVID-19. <b>Conclusions</b>: China has generated a plethora of guidelines covering almost all aspects of COVID-19. Chloroquine, as one widely affordable treatment, was recommended by Chinese national guidelines and provincial guidelines. Considering the continuous debates around Chloroquine, confirmatory studies with robust methodology are awaited to address the unanswered questions on its potential benefits and risks on COVID-19.</AbstractText><CopyrightInformation>© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Shuyao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabbous</LastName><ForeName>Monique</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yitong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Ru</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toumi</LastName><ForeName>Mondher</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7939-7204</Identifier><AffiliationInfo><Affiliation>Public Health Department, Aix Marseille University, Marseille Cedex 05, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mark Access Health Policy</MedlineTA><NlmUniqueID>101670174</NlmUniqueID><ISSNLinking>2001-6689</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chinese Guidelines</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">pharmaceutical Treatment</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33133431</ArticleId><ArticleId IdType="doi">10.1080/20016689.2020.1818446</ArticleId><ArticleId IdType="pii">1818446</ArticleId><ArticleId IdType="pmc">PMC7580738</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188</Citation><ArticleIdList><ArticleId IdType="pubmed">32164085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6(1):16</Citation><ArticleIdList><ArticleId IdType="pubmed">33731711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Mar 26;368:m1198</Citation><ArticleIdList><ArticleId IdType="pubmed">32217618</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Jul;81(1):147-178</Citation><ArticleIdList><ArticleId IdType="pubmed">32209384</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 28;323(16):1545-1546</Citation><ArticleIdList><ArticleId IdType="pubmed">32167538</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Apr;93:339-344</Citation><ArticleIdList><ArticleId IdType="pubmed">32198088</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation><ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation><ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000907 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000907 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33133431
|texte= Chinese guidelines related to novel coronavirus pneumonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33133431" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |